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Abstract
Objective—The purpose of this study was to determine whether metformin promotes weight loss
in overweight out-patients with chronic schizophrenia or schizoaffective disorder.
Method—In a double-blind study, 148 clinically stable, overweight (body mass index [BMI]
≥27) outpatients with chronic schizophrenia or schizoaffective disorder were randomly assigned to
receive 16 weeks of metformin or placebo. Metformin was titrated up to 1,000 mg twice daily, as
tolerated. All patients continued to receive their prestudy medications, and all received weekly diet
and exercise counseling. The primary outcome measure was change in body weight from baseline
to week 16.
Results—Fifty-eight (77.3%) patients who received metformin and 58 (81.7%) who received
placebo completed 16 weeks of treatment. Mean change in body weight was −3.0 kg (95% CI=
−4.0 to −2.0) for the metformin group and −1.0 kg (95% CI= −2.0 to 0.0) for the placebo group,
with a between-group difference of −2.0 kg (95% CI=−3.4 to −0.6). Metformin also demonstrated
a significant between-group advantage for BMI (−0.7; 95% CI=−1.1 to −0.2), triglyceride level
(−20.2 mg/dL; 95% CI=−39.2 to −1.3), and hemoglobin A1c level (−0.07%; 95% CI=−0.14 to
−0.004). Metformin-associated side effects were mostly gastrointestinal and generally transient,
and they rarely led to treatment discontinuation.
Conclusions—Metformin was modestly effective in reducing weight and other risk factors for
cardiovascular disease in clinically stable, overweight outpatients with chronic schizophrenia or
schizoaffective disorder over 16 weeks. A significant time-by-treatment interaction suggests that
benefits of metformin may continue to accrue with longer treatment. Metformin may have an
important role in diminishing the adverse consequences of obesity and metabolic impairments in
patients with schizophrenia.
The difference in life expectancy for patients with schizophrenia compared with the general
population is more than 20 years (1), and cardiovascular disease accounts for at least 50% of
this excess mortality (2). While the basis for increased cardiovascular disease in
schizophrenia is multifactorial, adverse metabolic side effects of antipsychotic medications
include increased risk for weight gain, hyperlipidemia, and impaired glucose metabolism (3–
Address correspondence to: Dr. Jarskog (jarskog@med.unc.edu).
Presented at the 65th annual meeting of the Society of Biological Psychiatry, New Orleans, May 20–22, 2010, and the 49th annual




Am J Psychiatry. Author manuscript; available in PMC 2014 September 01.
Published in final edited form as:













6). Studies suggest that antipsychotic-induced metabolic side effects can increase both the
10-year risk of cardiovascular disease (7) and mortality from cardiovascular disease (8).
Given the magnitude of the problem, surprisingly little evidence from randomized trials is
available to guide the management of antipsychotic-induced weight gain and related
metabolic deficits (9).
Among treatments approved by the U.S. Food and Drug Administration (FDA) for weight
loss, options for persons with schizophrenia are very limited. Sympathomimetics, such as
diethylpropion, phentermine, and a recently approved combination of phentermine and
topiramate, are relatively contraindicated given the potential risk for psychosis exacerbation.
In a 16-week study, orlistat, a pancreatic lipase inhibitor, produced no significant weight
loss in overweight patients with schizophrenia (10). The safety and efficacy of other weight
loss agents, including lorcaserin, a newly approved 5- HT2c agonist, and a combination of
naltrexone and bupropion currently under development, are unknown in schizophrenia.
Among agents without an FDA indication for weight loss, several recent meta-analyses
indicate that metformin, topiramate, sibutramine, fenfluramine, and reboxetine have modest
efficacy for antipsychotic-induced weight gain (9, 11), although only metformin and
topiramate are currently marketed in the United States.
Metformin is a well-tolerated biguanide antihyperglycemic approved for treatment of type 2
diabetes mellitus. Metformin normalizes blood glucose levels by blocking hepatic
gluconeogenesis and increasing peripheral insulin sensitivity (12). Since metformin does not
increase insulin production, it is rarely associated with hypoglycemia (13). Metformin is
known to cause modest weight loss in people with prediabetes and with type 2 diabetes (14,
15). Contributing mechanisms for weight loss are thought to include appetite suppression
and slowing of gastric emptying related to stimulation of glucagon-like peptide–1 secretion
(13, 16).
Studies of the use of metformin to produce weight loss or to prevent antipsychotic-induced
weight gain in non-diabetic patients with schizophrenia have demonstrated positive (17–21),
suggestive (22), and negative (23–25) results. A meta-analysis of available studies (N=7)
found weight loss of approximately 3 kg with metformin over 3 to 4 months (9), primarily in
narrowly defined populations, including children (19, 24), adults with first-episode
schizophrenia (17, 18, 20, 21), and predominantly non-obese individuals (17, 18, 22–25).
The present study is the first, to our knowledge, to examine whether metformin is effective
for weight loss in a typical sample of overweight adults with a chronic psychotic illness.
Method
Setting and Study Design
The study was conducted between March 2009 and February 2010 at 17 U.S. academic,
Veterans Affairs, and private research clinic sites affiliated with the National Institute of
Mental Health-funded Schizophrenia Trials Network (see the acknowledgment section for a
list of the research sites). In this double-blind randomized study, stable outpatients with
schizophrenia or schizoaffective disorder with a body mass index (BMI) ≥27 received 16
weeks of adjunctive metformin or placebo. The primary outcome measure was between-
group change in body weight over 16 weeks. It was hypothesized that metformin would
produce greater weight loss compared with placebo.
Study treatments were randomly assigned using a central computerized system, and eligible
participants received double-blind over-encapsulated metformin or placebo in a 1:1 ratio.
Randomization was stratified by site in blocks of four. All participants received a
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standardized behavioral intervention focused on improving diet and exercise habits. An
institutional review board approved the study at each research site.
Participants
Eligible participants were 18 to 65 years old; met criteria for schizophrenia or
schizoaffective disorder, as determined by the Structured Clinical Interview for DSM-IV;
had a duration of illness ≥1 year; had a BMI ≥27; had outpatient status; and were receiving
one or a combination of two FDA-approved antipsychotics with no change in antipsychotic
agents for 2 months and no change in dosage for 1 month prior to study entry. Concomitant
medications were allowed if dosages were unchanged for 1 month prior to entry. Women of
childbearing potential were required to use an acceptable method of birth control. All
participants provided written informed consent.
Exclusion criteria included inpatient status; a Clinical Global Impressions scale severity
rating (CGI-S) ≥6 (severely or very severely ill); diabetes mellitus; a fasting glucose level
>125 mg/dL; current or previous treatment with metformin; current treatment with insulin or
an oral hypoglycemic; treatment with more than two antipsychotics; use of any prescription
or nonprescription medication for weight loss within the past month; pregnancy or
breastfeeding; an uncorrected thyroid disorder; and any serious and unstable medical illness.
Rarely, metformin has been associated with lactic acidosis (3 in 100,000 patient-years), a
condition that often co-occurs with a serious medical condition and that can be potentiated
by excessive alcohol intake (13). To minimize the risk of lactic acidosis, individuals were
excluded if they had congestive heart failure, renal impairment (serum creatinine levels ≥1.5
mg/dL for men and ≥1.4 for women; estimated glomerular filtration rate <55 mL/min/ 1.73
m2), hepatic disease (ALT, AST, GGT levels >1.5 times the upper limit of normal; total
bilirubin level >1.2 times the upper limit of normal), metabolic acidosis (serum CO2 level
below the lower limit of normal), iodinated contrast material in the past month, or alcohol
abuse or dependence in the past month.
Intervention
Study treatments were double-blind, with identical capsules containing metformin (500 mg)
or placebo. After randomization, participants began treatment with one 500-mg metformin
capsule or matching placebo twice daily, to be taken with morning and evening meals for
the first week. If well tolerated, the study medication was then increased to one capsule in
the morning and two capsules in the evening for the following week and then increased to
the final dosage of two capsules twice daily at week 3. The maximum total daily dose for
metformin was 2,000 mg. During the titration period, the dosage could be reduced or the
drug discontinued for tolerability concerns. Following a reduction or interruption in the
dosage, study medication would be retitrated in one-capsule increments per week up to two
capsules twice daily or continued at the maximum tolerated dosage.
Behavioral Intervention
All participants received weekly diet and exercise counseling during the study. The
intervention was adapted from a weight-reduction program developed for patients with
severe mental illnesses (26). The intervention included eight 20- to 30-minute lessons and
seven interim telephone calls to reinforce lessons. (For details, see the data supplement that
accompanies the online edition of this article.)
Outcome Measures
The primary outcome measure was change in body weight from baseline to week 16.
Secondary outcome measures included change from baseline to week 16 in BMI, waist
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circumference, waist-hip ratio, and levels of fasting total cholesterol, non-high-density
lipoprotein (non-HDL) cholesterol, high-density lipoprotein (HDL) cholesterol, low-density
lipoprotein (LDL) cholesterol, triglycerides, glucose, insulin, and hemoglobin A1c (HbA1c).
Additional safety outcomes included the frequency and severity of adverse events (assessed
using a side effects scale adapted from the Clinical Antipsychotic Trials of Intervention
Effectiveness study [3]), vital signs, laboratory measures (for estimated glomerular filtration
rate and creatinine, ALT, AST, and lactate levels), and CGI-S ratings. Weight and vital signs
were assessed at screening, at baseline, weekly during the first 2 weeks of treatment, and
then every 2 weeks until week 16 or treatment discontinuation. Laboratory blood tests were
obtained at screening, baseline, and weeks 4, 8, 12, and 16; CGI-S ratings were determined
at screening, at baseline, and monthly until week 16.
Statistical Analysis
Participants who were screened but not randomly assigned were not included in efficacy or
safety analyses. Efficacy was assessed for participants who received at least one dose of
study medication and had at least one postbaseline weight measure (i.e., the intent-to-treat
population). A linear mixed-model analysis was used to compare treatment groups with
respect to least-squares-mean estimates of change in body weight from baseline to week 16.
The mixed model used data from all visits for which the participant was receiving the study
drug and included fixed effects for treatment group, visit, and treatment-by-visit interaction
and random effects for participant and site. Only visits that occurred after participants
discontinued the study drug and did not restart it were excluded from the analysis. A similar
approach was used to compare continuous secondary efficacy and safety outcome variables.
Graphical representation of change in primary outcome over the follow-up period was based
on least-squares-mean estimates of change for each group and associated 95% confidence
intervals.
Safety analyses were performed for participants who received at least one dose of the study
drug and included any event occurring between the time of the first dose and within 30 days
of discontinuation of the study drug.
The target sample size of 148 participants was estimated to yield 80% power to detect a 2-kg
(SD=4) difference in weight change between the treatment groups, assuming a two-tailed
test with an alpha level of 0.05 (18, 19, 27).
Results
Randomization and Baseline Characteristics
A total of 193 individuals consented to participate in the study, and 148 were found eligible
and randomly assigned to receive metformin or placebo. Of these, 75 received metformin
and 71 received placebo. Two participants in the placebo arm withdrew before receiving
study medication. Fifty-eight (77.3%) participants who received metformin and 58 (81.7%)
who received placebo completed 16 weeks of treatment. (The CONSORT flowchart is
presented in the online data supplement.) The baseline demographic and clinical
characteristics of the intent-to-treat population are summarized in Table 1. For the baseline
distribution of antipsychotic medications and concomitant medications commonly
associated with weight gain, see Table S1 in the data supplement.
Weight and BMI
Least-squares-mean body weight change across the 16-week treatment period was −3.0 kg
(95% confidence interval [CI]= −4.0 to −2.0) for the metformin group and −1.0 kg (95%
CI=−2.0 to 0.0) for the placebo group, with a between-group difference of −2.0 kg (95%
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CI=−3.4 to −0.6; p=0.007) (Figure 1, Table 2). The between-group difference demonstrated
a significant time-by-treatment interaction (p=0.007). In the active treatment arm, the mean
final daily dose of metformin was 1,887 mg (SD=292). Over 16 weeks, participants who
received metformin experienced a 2.8% weight reduction, compared with a 1.0% reduction
among those who received placebo. Thirteen (17.3%) participants who received metformin,
compared with seven (9.8%) who received placebo, lost more than 5% of their baseline
weight. BMI changed by −1.0 (95% CI=−1.3 to −0.7) in the metformin group and by −0.3
(95% CI=−0.7 to 0.0) in the placebo group, with a between-group difference of −0.7 (95%
CI=−1.1 to −0.1; p=0.006).
Lipid Measures
Triglyceride levels changed by −7.0 mg/dL (95% CI= −20.4 to 6.3) in the metformin group
and by 13.2 mg/dL (95% CI=−0.3 to 26.7) in the placebo group, with a between-group
difference of −20.2 mg/dL (95% CI=−39.2 to −1.3; p=0.037) and a significant time-by-
treatment interaction (p=0.04). Between-group differences for met-formin and placebo fell
short of statistical significance for levels of non-HDL cholesterol (−9.0 mg/dL, 95%= CI=
−18.3 to 0.2; p=0.054) and total cholesterol (−9.2 mg/dL, 95% CI=−18.6 to 0.3; p=0.057).
Similarly, no differences emerged for HDL and LDL cholesterol levels (Table 2).
Indices of Glucose Metabolism
Changes in fasting glucose and insulin levels did not differ between the metformin and
placebo groups (Table 2). Mean HbA1c levels changed by −0.06% (95% CI=−0.11 to −0.01)
in the metformin group and 0.011% (95% CI=−0.04 to 0.06) in the placebo group, with a
between-group difference of −0.07% (95% CI=−0.14 to −0.004; p=0.04) and a significant
time-by-treatment interaction (p=0.039).
Adherence to Treatment
In the intent-to-treat population, 94.9% of participants in the metformin group and 96.0% in
the placebo group demonstrated adherence to study medication across all study visits either
all (81%–100%) or most (61%–80%) of the time, based on pill counts, patient report, and
any other available information, with no between-group differences. For the behavioral
intervention, 84.9% of participants receiving metformin and 89.7% of those receiving
placebo exhibited reasonable-to-excellent adherence based on patient report and rater
assessment, with no between-group differences.
Adverse Events and Safety Assessments
Ten serious adverse events (metformin group, N=3; placebo group, N=7) were reported.
None were attributed to metformin. A systematic inquiry about seven side effects commonly
associated with metformin and rated at severity levels of “moderate” or “severe” is
summarized in Table 3. Only diarrhea was reported significantly more frequently with
metformin (33.3%) than placebo (16.9%). The side effects were generally transient. Eleven
of the 75 (14.7%) participants receiving metformin and eight of the 71 (11.3%) participants
receiving placebo discontinued the study treatment because of intolerability. Two
participants in the metformin group discontinued treatment because of abdominal symptoms.
In all, 17 participants discontinued metformin and 13 discontinued placebo before the end of
the 16-week treatment period.
Safety assessments for vital signs, for levels of ALT, AST, and creatinine, and for estimated
glomerular filtration rate revealed no change in both groups. Lactate levels demonstrated a
small increase in the metformin group (mean=0.240 mmol/L, 95% CI=0.06–0.42) compared
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with the placebo group (mean=−0.07 mmol/L, 95% CI=−0.24 to 0.11), with a mean group
difference of 0.31 mmol/L (95% CI=0.06–0.56; p=0.02).
Recent illicit drug use was reported in at least one study visit by 10 participants in the
metformin group (cocaine, opiate, or cannabis use) and eight in the placebo group (cocaine,
opiate, or cannabis use). No between-group differences emerged.
Exploratory Analyses
We explored the effect of age and baseline BMI using a median split and the effect of sex,
antipsychotic medication, smoking status, and presence or absence of nausea, vomiting, or
diarrhea (during the first 2 weeks of study treatment) as categorical variables on metformin-
placebo weight change. A priori, antipsychotic medications were categorized as having
“higher” or “lower” risk for causing weight gain (see Table 1 footnotes), based on published
data (3, 6, 28, 29). Exploratory analyses revealed significant metformin-placebo weight
reductions in the following groups: younger-age participants (<44 years old), participants
with a baseline BMI <33.38, men, and nonsmokers (Table 4).
Discussion
In this study, treatment with metformin over 16 weeks, along with weekly diet and exercise
counseling, was associated with significantly more weight loss (2.0 kg) than placebo in
overweight adult outpatients with chronic schizophrenia or schizoaffective disorder. The
weight change corresponds to a BMI reduction of 1.0 with metformin and an advantage of
−0.7 for metformin over placebo. Unlike previous studies, this study placed no restrictions
on the timing of weight gain, the chronicity of psychosis, or the presence of comorbid
psychiatric conditions. Furthermore, patients could be on a regimen of any single
antipsychotic medication or any combination of two antipsychotic medications as well as
stable dosages of other concomitant medications. The only medical exclusions were for
diabetes and conditions that could increase risk for metformin-induced lactic acidosis. Taken
together, these factors suggest that the results are generalizable and applicable to a broad
group of patients.
An increase of one BMI unit has previously been identified as an important threshold for
triggering an intervention to address weight gain in patients receiving antipsychotic
medication (30). While this study suggests that metformin can reasonably be expected to
lead to loss of one BMI unit, it is also clear that the magnitude of needed weight loss in this
population often exceeds the demonstrated effects of 16 weeks of metformin. It would be
important to determine whether metformin-associated weight loss in overweight patients
receiving antipsychotics can extend beyond 16 weeks, as suggested by the linear time-by-
treatment interaction. Continued weight loss with metformin is also supported by a study of
84 mostly nonobese female patients with first-episode schizophrenia and amenorrhea that
demonstrated significant weight loss with 6 months of metformin compared with placebo
(20), as well as evidence of modest weight loss for up to 12 months in patients with
prediabetes and type 2 diabetes (14, 15).
Other approaches to promote weight loss among people diagnosed with schizophrenia are
limited. Topiramate is the only adjunctive agent other than metformin marketed in the
United States that has demonstrated significant weight loss (approximately 2.5 kg) in a
meta-analysis (9). The other main pharmacological approach to weight loss in this
population is to switch to an antipsychotic with lower weight-gain liability. Studies have
demonstrated comparable modest weight loss using this method (31, 32). Although
switching in these studies was generally safe and did not lead to widespread relapses,
switching antipsychotics must be undertaken with considerable care and close clinical
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monitoring. Taken together, the evidence suggests that metformin represents one of the few
safe and modestly effective approaches for overweight patients receiving antipsychotics who
are also committed to making healthy lifestyle changes consistent with weight loss.
Among previous studies of metformin for antipsychotic-induced weight gain, many have
focused on adults with first-episode schizophrenia. In 128 Chinese adults with first-episode
schizophrenia (the largest previous study) who had gained >10% of their baseline weight
since starting antipsychotics, metformin was associated with a mean weight loss of 4.7 kg
after 12 weeks of treatment together with a daily behavioral intervention, while the
behavioral intervention alone produced a mean weight loss of 1.4 kg (18). Comparing those
findings with our data suggests that metformin may be somewhat more effective for weight
loss in patients with first-episode psychosis. In adults with chronic multiepisode psychosis,
previous metformin studies have been smaller with mostly nonobese participants. Two
studies found no significant metformin-placebo weight change: the first examined 40
inpatients (mean BMI, approximately 23) starting olanzapine (25), and the second examined
80 inpatients and outpatients (mean BMI, approximately 25.5) who were stable on
olanzapine (23). A study of 61 chronic patients receiving clozapine (mean BMI,
approximately 28) found a small metformin-placebo difference over 14 weeks, but only in a
completer analysis (22). The present study represents the largest study to date of metformin
in antipsychotic-treated patients (N=146) and extends previous findings to a more typical
group of substantially overweight patients receiving antipsychotics.
Although our cohort was not selected for lipid abnormalities, their mean baseline levels of
triglycerides, non-HDL cholesterol, LDL cholesterol, and HDL cholesterol were at or near
unhealthy levels (33). For triglycerides, the metformin-placebo difference was −20 mg/mL.
While this effect reflected, in part, a triglyceride increase in the placebo arm, the pattern is
consistent with the effects of metformin on triglycerides in type 2 diabetes (14, 34), and the
significant time-by-treatment interaction suggests the potential for continued improvement.
In the largest previous study of metformin in first-episode schizophrenia, lipids were not
measured (18). In a study of patients receiving clozapine, no differential effect of metformin
was found on lipids (22). Our study provides evidence that metformin may improve
cardiovascular disease risk in overweight patients with schizophrenia.
No changes in fasting glucose or insulin levels were demonstrated between the metformin
and placebo groups, although a small between-group difference was found for HbA1c levels
(−0.07%), which also revealed a significant time-by-treatment interaction. These results
contrast with findings from a study of patients with first-episode schizophrenia in which
metformin was associated with a 50% reduction of fasting insulin levels compared with
placebo (18). This could reflect distinct pathophysiological, pharmacogenetic, and dietary
differences between the two populations studied. Although mean glucose and insulin levels
did not change in our study, the benefits of metformin in preventing the onset of diabetes in
prediabetic individuals (15) suggest that diabetes prevention is another potential long-term
benefit for overweight patients with schizophrenia who are receiving metformin.
In exploratory analyses, younger age (<44 years old), lower BMI (<33), male sex, and
nonsmoking status were significantly associated with metformin-associated weight loss. The
evidence that younger patients who are not morbidly obese appear to exhibit greater
metformin-placebo weight loss appears to be consistent with previous studies of metformin
in first-episode psychosis that found somewhat more weight loss than we observed in the
present study (18, 20). The lack of significant metformin-associated weight loss in female
patients is likely confounded by the relatively small percentage of women (approximately
30%). Smoking has been associated with lower body mass and reduced appetite (35), and
given that appetite suppression has been linked to metformin (16), the appetite-suppressing
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effects of smoking may have reduced the potential for metformin-induced weight loss.
While these associations could represent important predictors of weight loss response to
metformin, they must be interpreted cautiously given that the study was not powered to test
these post hoc analyses.
Metformin was generally well tolerated by participants. No serious adverse events were
attributed to metformin. While the frequency of adverse events was relatively high, the
difference between metformin and placebo was generally small. Gastrointestinal symptoms
were more common in the metformin group, but most of these were transient, and only
diarrhea was substantially more common in the metformin group compared with the placebo
group. Of the 19 participants who discontinued the study medication because of
unacceptable side effects, 11 received metformin and eight received placebo.
The study did not follow participants after discontinuation of metformin, and therefore it
remains unknown whether and when any weight lost might be regained. Furthermore,
because an important goal was to obtain results with broad generalizability, the study did not
standardize antipsychotic treatment or exclude concomitant medications with a risk for
weight gain. However, weight change in participants receiving antipsychotics associated
with higher compared with lower risk for causing weight gain did not differ between the
metformin and placebo groups. Another potential confounder was the lack of
standardization of caloric intake and physical activity. Analysis of adherence to the
behavioral intervention suggested that adherence was high and similar between the groups.
However, it is uncertain how well patients in clinical practice can modify their diet and
activity level in a manner similar to that achieved in this study and whether less frequent
behavioral counseling could also be effective.
Conclusions
This double-blind randomized controlled trial demonstrates the efficacy of metformin to
achieve weight loss in overweight outpatients with schizophrenia or schizoaffective
disorder. While the benefit of metformin on weight was modest, there are few alternatives
for this patient population. For example, switching antipsychotic agents may not be
appropriate for patients already receiving an agent with lower risk for causing weight gain or
for patients for whom risks to clinical stability are considerable, such as for those receiving
clozapine. Metformin represents a safe and reasonable option for overweight patients who
are motivated to lose weight. It should be further emphasized that weight loss with any
pharmacological intervention is more likely when accompanied by concurrent modifications
of diet and physical activity levels.
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The Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia
(METS) Study investigators and sites were as follows: Lawrence Adler, M.D., Clinical
Insights, Glen Burnie, Md.; Michael Barber, M.D., Baylor College of Medicine, Houston;
Matthew Byerly, M.D., University of Texas-Southwestern, Dallas; Jose M. Canive, M.D.,
New Mexico VA Health Care System, Albuquerque, N.Mex.; Ira Glick, M.D., Stanford
University, Palo Alto, Calif.; David C. Henderson, M.D., Massachusetts General Hospital/
Freedom Trail Clinic, Boston; L. Fredrik Jarskog, M.D. (during subject enrollment period),
New York State Psychiatric Institute/Columbia University, New York; J. Steven Lamberti,
M.D., University of Rochester Medical Center, Rochester, N.Y.; Ahsan Khan, M.D.,
Clinical Research Institute, Wichita, Kan.; Joseph P. McEvoy, M.D., Duke University,
Durham, N.C.; Herbert Meltzer, M.D., Vanderbilt University, Nashville; Alexander Miller,
M.D., University of Texas Health Science Center at San Antonio; Del D. Miller, M.D.,
University of Iowa, Iowa City; Henry A. Nasrallah, M.D., University of Cincinnati; Stephen
Olson, M.D., University of Minnesota, Minneapolis; Jayendra K. Patel, M.D., University of
Massachusetts Medical School, Worcester; and Bruce L. Saltz, M.D., Mental Health
Advocates, Boca Raton, Fla.
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FIGURE 1. Weight Change Across 16 Weeks of Treatment With Metformin or Placebo in
Overweight Outpatients With Schizophrenia or Schizoaffective Disordera
aError bars represent 95% confidence intervals. Significantly different between groups,
p=0.007.
Jarskog et al. Page 12






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Jarskog et al. Page 17
TABLE 4
Exploratory Moderators of Metformin-Placebo Weight Change in Overweight Outpatients With Schizophrenia
or Schizoaffective Disorder
Variable N Weight Change (kg) 95% CI p
Age (years)a
 <44 74 −3.2 −5.4 to −1.0 0.005
 ≥44 72 −1.0 −2.9 to 0.8 0.276
Baseline body mass indexa
 <33.38 73 −1.9 −3.6 to −0.2 0.028
 ≥33.38 73 −2.0 −4.2 to 0.3 0.088
Sex
 Female 45 −1.7 −4.0 to 0.6 0.140
 Male 101 −2.1 −3.9 to −0.3 0.020
Antipsychotic medicationb
 Higher risk for weight gain 83 −1.5 −3.2 to 0.1 0.074
 Lower risk for weight gain 47 −2.3 −5.4 to 0.9 0.157
Tobacco use
 Nonsmokers 80 −2.6 −4.3 to −0.8 0.005
 Smokers 66 −1.2 −3.5 to 1.2 0.323
Nausea, vomiting, or diarrheac
 Present 83 −1.9 −3.9 to 0.2 0.072
 Absent 63 −1.9 −4.0 to 0.2 0.070
a
Analyzed using a median split.
b
Participants receiving one higher- and one lower-risk agent (N=16) were not included in this analysis. (For a list of higher- and lower-risk agents,
see Table 1 footnotes.)
c
Data refer to the presence or absence of nausea, vomiting, or diarrhea within the first 2 weeks of study medication.
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